Pfizer and Germany partner BioNtech have applied for Emergency Use Authorisation (EUA) from the US Food and Drug Administration (FDA) for their COVID-19 vaccine candidate. The Pfizer vaccine has shown 95 percent efficiency against the deadly coronavirus. This is considered the first major step to aid the eradication of the deadly coronavirus. The application was made in a video posted on the official website of the company, Reuters quotes Pfizer Chief Executive officer. This is the first COVID-19 vaccine to seek regulatory clearance in the US. During the phase 3 trial, the vaccine was 95% effective with no major side effects. FDA panel will discuss emergency use of the vaccine on 10th Dec.